Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Boundless Bio, Inc./ 4

SEC Filing · 4

Boundless Bio, Inc.

BOLDNASDAQEQUITYCurrent

SEC Filing

Filed Jul 16, 2026Accepted Jul 16, 2026, 8:10 PM EDTCIK 1782303Accession 0001178579-26-000015
View company →Permanent SEC source ↗
Share

Company context

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. For more information, visit https://boundlessbio.com/.

Current securities

BOLDNASDAQ · EQUITY · Current

Recent company filings

  1. 425 filingAug 28, 2026
  2. Entry into a Material Definitive AgreementAug 28, 2026
  3. 10-Q filingAug 7, 2026
  4. 4 filingJul 21, 2026
  5. 4 filingJul 13, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗